NDA 213217 · Beone Medicines USA
Brukinsa
Zanubrutinib · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Jan 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Nov 14, 2019
Approved uses
6
Original approval plus efficacy supplements
Registered trials
219
20 Phase 3, 77 recruiting
FAERS reports
4,539
3,384 serious, 505 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 4, 2026.
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.1 Mantle Cell Lymphoma BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Waldenström's Macroglobulinemia BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) [see Clinical...
Mechanism: Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. In nonclinical studies, zanubrutinib inhibited malignant B-cell proliferation and reduced tumor growth.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 7, 2024 Supplement 11 · Efficacy OrphanLabelLetter
- Dec 21, 2023 Supplement 9 · Efficacy OrphanLabelLetter
- Jan 19, 2023 Supplement 7 · Efficacy OrphanLabelLetterReview
- Sep 14, 2021 Supplement 5 · Efficacy · priority review OrphanLabelLetter
- Aug 31, 2021 Supplement 4 · Efficacy OrphanLetterLabelReview
- Nov 14, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
1 products under this application
- BRUKINSA · ZANUBRUTINIB 80MG · CAPSULE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Zanubrutinib" as an intervention, any sponsor and status, largest first.
- MACE and BTK InhibitorsNot yet recruiting
University Hospital, CaenAcademic, hospital or other
NCT07923162 · 10,000 participants (planned) · Start Dec 1, 2026 · Primary completion Feb 1, 2027
Drug: ibrutinib; Acalabrutinib and 1 more · For: Hematologic Cancer; MACE; BTK Inhibitors
Sites: Caen, France
- A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibPivotal-lookingActive, not recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04170283 · 955 participants · Start Jan 16, 2020 · Primary completion Dec 31, 2026
Drug: Zanubrutinib; Tislelizumab · For: B-cell Malignancies
Sites: Gilbert, Arizona; Little Rock, Arkansas; Centennial, Colorado · 153 sites in all
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT03740529 · 803 participants · Start Mar 15, 2019 · Primary completion Jan 27, 2025
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma and 3 more
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 56 sites in all
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaPivotal-lookingActive, not recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT05100862 · 799 participants · Start Mar 10, 2022 · Primary completion Jul 2028
Drug: Zanubrutinib; Rituximab and 2 more · For: Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma
Sites: Fresno, California; Irvine, California; Los Alamitos, California · 264 sites in all
- A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03734016 · 652 participants · Start Nov 1, 2018 · Primary completion Aug 8, 2022
Drug: Zanubrutinib; Ibrutinib · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Little Rock, Arkansas; Los Angeles, California; Boulder, Colorado · 115 sites in all
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Pivotal-lookingActive, not recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT06073821 · 652 participants (planned) · Start Nov 11, 2023 · Primary completion Feb 2032
Drug: Sonrotoclax; Zanubrutinib and 2 more · For: CLL
Sites: Anchorage, Alaska; Duarte, California; La Jolla, California · 201 sites in all
- A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLPivotal-lookingActive, not recruiting
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT03336333 · 590 participants · Start Oct 31, 2017 · Primary completion May 7, 2021
Drug: Zanubrutinib; Bendamustine and 2 more · For: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Augusta, Georgia; Chicago, Illinois; Boston, Massachusetts · 158 sites in all
- A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationPivotal-lookingActive, not recruiting
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04002297 · 510 participants · Start Aug 20, 2019 · Primary completion Apr 27, 2026
Drug: zanubrutinib; bendamustine and 1 more · For: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Sites: Orange, California; Chicago, Illinois; Boston, Massachusetts · 176 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use585
- disease progression318
- myelosuppression254
- fatigue249
- anaemia247
- white blood cell count decreased247
- contusion241
- platelet count decreased219
- rash212
- death211
- pneumonia201
- diarrhoea185
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 17 |
| 2020 | 89 |
| 2021 | 152 |
| 2022 | 437 |
| 2023 | 733 |
| 2024 | 926 |
| 2025 | 1,195 |
| 2026 | 989 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Brukinsa (Zanubrutinib)
2024 spending
$1.72B
Beneficiaries
18,031
130,764 claims
Per beneficiary
$95,633
$121.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,508,807 |
| 2021 | $82,575,005 |
| 2022 | $303,322,613 |
| 2023 | $801,426,531 |
| 2024 | $1,724,363,414 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation.
Kumar A, Soumerai J, Abramson JS, et al. · Blood 2025 · Clinical Trial, Phase II, Multicenter Study
- Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR, Eichhorst B, Hillmen P, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Multicenter Study
- Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
Shadman M, Munir T, Robak T, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial.
Tam CS, Brown JR, Kahl BS, et al. · Lancet Oncol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.
Brown JR, Eichhorst B, Lamanna N, et al. · Blood 2024 · Comparative Study, Randomized Controlled Trial
- Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Dimopoulos MA, Opat S, D'Sa S, et al. · J Clin Oncol 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: BeOne Medicines (BeiGene)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.